We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Real-Time Levodopa Level Monitoring in Parkinson Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04735627
Recruitment Status : Recruiting
First Posted : February 3, 2021
Last Update Posted : November 2, 2022
Information provided by (Responsible Party):
Irene Litvan, University of California, San Diego

Brief Summary:
This project aims to develop a minimally invasive microneedle sensor to monitor levodopa levels in real time. We will test the accuracy, tolerability, and safety of this device in people with Parkinson disease.

Condition or disease Intervention/treatment Phase
Parkinson Disease Device: Levodopameter Not Applicable

Detailed Description:

People with Parkinson disease (PD) lack the chemical dopamine, which is important for movement. Levodopa replaces dopamine and restores normal motor function in PD. Early in the disease stages, people with PD benefit significantly from levodopa. However, as PD progresses, the brain loses more dopamine-producing cells, which causes motor complications and unpredictable responses to levodopa. To maintain control of symptoms over time, levodopa doses must be increased and given at increasingly shorter intervals. The optimal levodopa regimen is different for each person and may vary from day-to-day, depending on a variety of internal and external factors including meal consumption, activity level, and other lifestyle variances. Currently, clinicians assess levodopa's benefit by the patient's testimony and by clinical exam. However, these methods may not adequately represent the severity or range of complications experienced by the PD patient. Thus, it can be difficult to determine the optimal levodopa treatment regimen, which can cause suboptimal disease management and side effects.

This project aims to develop a continuous, minimally invasive microneedle device placed on the skin (the "Levodopameter") designed to continuously measure levodopa levels in real time, with the future goals of identifying an individualized treatment regimen for people with PD to improve disease management. We will compare levodopa levels measured by the Levodopameter to the impractical and expensive "gold standard" high-performance liquid chromatography (HPLC) analysis of plasma levodopa levels. We will first test the device after administering oral carbidopa/levodopa in 10 participants with PD. After that portion of the study is completed and safety confirmed, we will test the device in 10 participants with PD after administering carbidopa and intravenous levodopa. We will also evaluate the device's safety and tolerability.

The long-term goal of this device is to allow PD patients to take proactive measures to assess and maintain an optimal, personalized levodopa regimen, similar to diabetes care in which diabetic patients periodically self-monitor their glucose and adjust their insulin regimen accordingly.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Participants will receive either oral carbidopa and either oral or intravenous levodopa and the minimally invasive experimental device will measure levodopa levels in interstitial fluid, which will be compared to plasma levodopa levels measured using high-performance liquid chromotography.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Real-Time Levodopa Monitoring for Improved Management of Parkinson Disease
Actual Study Start Date : December 7, 2021
Estimated Primary Completion Date : December 2027
Estimated Study Completion Date : February 2028

Resource links provided by the National Library of Medicine

Drug Information available for: Levodopa

Arm Intervention/treatment
Experimental: Levodopameter
During the single study visit, participants will receive either: 1) two separate doses of oral levodopa in a dose equivalent to their home regimen with one dose of carbidopa in a 1:10 ratio and one dose of carbidopa in a 1:4 ratio (carbidopa:levodopa) ratio; or will receive 2) one dose of oral carbidopa 100mg followed by intravenous levodopa in 1.2mg/kg dose. levodopa The Levodopameter microneedle sensor device will serially measure interstitial fluid levodopa levels and blood will be simultaneously collected from an intravenous line for high-performance liquid chromotography analysis of plasma levodopa levels.
Device: Levodopameter
The device is a microneedle sensor that can detect levodopa levels in the interstitial fluid.

Primary Outcome Measures :
  1. Levodopa Levels [ Time Frame: through study completion, an average of 12 months ]
    Data analysis from this first-of-its-kind microneedle levodopa monitoring device is necessarily exploratory and descriptive. We will assess the Levodopameter's feasibility and accuracy by comparing its interstitial fluid levodopa measurements to plasma levodopa levels analyzed by high-performance liquid chromatography.

Secondary Outcome Measures :
  1. Patient Acceptability of Levodopameter [ Time Frame: through study completion, an average of 12 months ]
    Participants will rate acceptability of the Levodopameter using a symmetric Likert-style questionnaire ranging from 1 (strongly disagree) to 5 (strongly agree) to rate the device's comfort, ease of wear, and other qualities. Averaged acceptability ratings of 4 and higher (agree or strongly agree) would indicate the participant's agreement on the device acceptability.

  2. Device Safety [ Time Frame: through study completion, an average of 12 months ]
    The investigators will monitor for and categorize the adverse events related to the device using the will be classified using the current version of the Common Terminology Criteria for Adverse Events.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Participants must meet the Movement Disorders Society (MDS) diagnostic criteria for clinically established Parkinson disease.
  2. Able to provide signed informed consent (in English or Spanish)
  3. Mild, moderate, or severe Parkinson disease, able to ambulate (Hoehn and Yahr stages I-IV)
  4. Taking instant release oral carbidopa/levodopa therapy
  5. Either not taking, or on stable doses of any of the following antiparkinsonian medications: dopamine agonists, monoamine oxidase B (MAO-B) inhibitors or catecholamine O-methyl transferase (COMT) inhibitors

Exclusion Criteria:

  1. Other neurological conditions including but not limited to stroke, dementia (including Parkinson disease dementia), or traumatic brain injury
  2. Co-existent major psychiatric disease
  3. Uncontrolled, active medical conditions (e.g., heart, kidney, or liver failure, diabetes, etc.)
  4. Status post deep brain stimulation (DBS) device placement
  5. Any other condition, that in the opinion of the investigators, would place the participant at risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04735627

Layout table for location contacts
Contact: Michael Skipworth 858-246-2537 mskipworth@health.ucsd.edu
Contact: Katherine Longardner, MD klongardner@health.ucsd.edu

Layout table for location information
United States, California
University of California San DIego Recruiting
San Diego, California, United States, 92093
Contact: Michael Skipworth       mskipworth@health.ucsd.edu   
Principal Investigator: Irene Litvan, MD         
Principal Investigator: Joseph Wang, PhD         
Sub-Investigator: Katherine Longardner, MD         
Sponsors and Collaborators
University of California, San Diego
Layout table for investigator information
Principal Investigator: Irene Litvan, MD UCSD
  Study Documents (Full-Text)

Documents provided by Irene Litvan, University of California, San Diego:
Informed Consent Form  [PDF] November 23, 2021

Brunetti B, Valdés-Ramírez G, Litvan I, Wang J. A disposable electrochemical biosensor for L-DOPA determination in undiluted human serum. Electrochemistry Communications 2014. p. 28-31.
Windmiller JR, Wang J. Wearable electrochemical sensors and biosensors: a review.: Electroanalysis; 2013. p. 29-46.

Layout table for additonal information
Responsible Party: Irene Litvan, Director of the UCSD Parkinson and Other Movement Disorders Center, University of California, San Diego
ClinicalTrials.gov Identifier: NCT04735627    
Other Study ID Numbers: 201535
First Posted: February 3, 2021    Key Record Dates
Last Update Posted: November 2, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases